The present invention relates to a preparation method for a compound of Mod.I crystal form of 4-(4-chloroanilino)-7-(2-methylaminocarbonyl-4-oxymethyl)pyridylfuro [2,3-d]pyridazine mesylate (EOC315), crystal form characterizations thereof, and pharmaceutical use thereof.